anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Obesity poses a significant global health challenge, with profound implications for women's reproductive health. The relationship between ovarian reserve and body mass index (BMI) remains a subject of debate. While obesity is generally associated with poorer outcomes in assisted reproductive technology (ART), the evidence remains inconclusive. This study aimed to investigate the effect of pre-pregnancy BMI on ovarian reserve and ART outcomes in infertile patients.
METHODS: We conducted a retrospective cohort study involving women who underwent in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) procedures at Tongji Hospital between 2016 and 2023. The study included 30,746 initial fresh cycles and 5,721 singleton deliveries. Patients were stratified by age and further categorized into four BMI groups: lean (< 18.5 kg/m²), normal weight (18.5-24.9 kg/m²), overweight (25.0-29.9 kg/m²), and obese (≥ 30.0 kg/m²). The primary endpoints of the study were pregnancy and perinatal outcomes. To explore the association between BMI and these outcomes, we adjusted for relevant confounding factors and utilized multivariate linear regression models, complemented by multifactorial logistic regression analyses.
RESULTS: Anti-Müllerian hormone (AMH) levels were significantly lower in the overweight and obese groups compared to the normal weight group. After adjusting for age, a negative correlation was found between AMH and BMI in the age subgroups of 20-30 and 30-35 years. Among women aged 20-35 years, those in the overweight and obese groups had significantly fewer retrieved oocytes, mature oocytes, and two-pronuclear (2PN) embryos than their normal weight counterparts. Despite these differences, pregnancy outcomes in the overweight and obese groups were comparable to those in the normal weight group across all age categories. Additionally, obesity was linked to an increased risk of gestational diabetes mellitus, hypertensive disorders of pregnancy, and macrosomia.
CONCLUSIONS: An age-related decrease in AMH levels was evident with increasing BMI. Although being overweight or obese is associated with poorer embryo and perinatal outcomes, it does not seem to have a substantial impact on fertility.
GABA is an inhibitory neurotransmitter that is found primarily in the brain. High GABA levels result in low levels of dopamine, another neurotransmitter that is the brain's "feel good" chemical and which plays a primary role in cocaine drug addiction. Cravings for cocaine can be reduced by lowering dopamine levels. This makes GABA-altering medications a potential treatment for cocaine addiction. This study will involve five GABA enhancing medications: tiagabine, topiramate, valproic acid, baclofen, and progesterone. The purpose of the study is to evaluate the interaction between GABA medications and cocaine in terms of safety and craving responses. In turn, these findings may guide future cocaine pharmacotherapy trials.

This 6-day inpatient study will begin with an orientation session to familiarize participants with study procedures. The evening of Day 1, all participants will receive placebo medication. On Days 2 through 4, participants will receive one of five GABA medications. The GABA medications will be given in gradually increasing doses to attain therapeutic levels while maintaining safety and minimizing side effects. Three experimental cocaine sessions will take place; one while the participants are receiving the placebo medication and two while the participants are receiving the GABA medications. During these sessions, cocaine will be administered intravenously in three increasing doses, each separated by 30-minute intervals. This will allow the participants' subjective and physiological responses during cocaine administration to return to baseline levels before the next dose. Blood will be drawn after each dose; heart rate, blood pressure, and an ECG will be monitored throughout the sessions. At the end of each session, questionnaires will be administered to assess the effects of cocaine and related mood states, as well as allow the participants to report any adverse events, depression, craving, or withdrawal symptoms.

This study is now closed and published.
In Arm 1, we will examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each participant's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across participants, but each individual will receive treatment at each duration. Resurgence will be tested following each treatment duration.
In the controlled retrospective follow up, (not random) 44 families participated with their 81 children and siblings. The intervention group included 18 families who participated in the "Maccabi Active" program (obesity treatment) in the years 2012-2013 in the northern district, with their 24 children (18 overweight children and 6 siblings). The control group included 26 families with their 57 children (27 children who had been overweight or obese in the years 2012-2013 when they were 8-14 years old and their 30 siblings). These families did not take part in a family based treatment for their overweight child. The parameters were measured at one set point time. All participants from both the control and research groups were evaluated at the follow-up and the data collected at follow-up is being reported collectively for the Retrospective Controlled Research branch.
The pharmacist will help the mother find a primary care physician if she doesn't have one, obtain health insurance if she doesn't have any, and discuss any health-related information about herself or her child, as needed. These pharmacist interactions will occur 7 days after baseline and again 1 month later (the participant will be asked to measure and text their blood pressure again 1 time per day for 3 days during the follow-up month). If the participant's blood pressures become elevated, the pharmacist will provide behavioral and lifestyle interventions to attempt to lower the blood pressure. They may also recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed, as necessary.
PROBLEM TO BE SOLVED: To obtain an aerosol composition having and excellent deodrizing effect, comfortable natural dry touch and stability. SOLUTION: This aerosol composition contains 0.01-20wt.% of aluminum octenylcinnamic acid corn starch ester and 0.01-20wt.% of an inorganic powdery material comprising a water-soluble metal salt (e.g. chlorohydroxy aluminum). The aerosol composition further contains 0.01-20wt.% of a spherical silicone resin having an average particle diameter of 1.0-10μm, 0.01-10wt.% of a nonionic surfactant having an HLB of <8, and 5-99wt.% of a propellant (e.g. liquified gas). The aerosol composition may further suitably contain one or more kinds of known compounds such as a sterilizer, oils and fats, a wax, a silicone compound, an antiseptic, a UV light absorbent, a chelating agent, a humectant, a thickener, water, a refreshing agent, an antiinflammatory agent, an amino acid, a plant extract and a clathrate compound.
Participants will receive TG-1701, oral dose in combination with ublituximab, oral dose and umbralisib, fixed IV infusion on specific Days of Cycles 1 and 2, followed by maintenance infusions in Cycles 3 to 6 (Cycle=28 days). As per protocol v6.0, participants from this arm will be transitioned to the long-term extension arm to receive TG-1701 monotherapy.
Intradural spinal cord arteriovenous shunts are challenging vascular lesions with poor prognosis if left untreated. Therapeutic options include endovascular treatment, microsurgery or a combined approach. Surgical approaches are more complex if the lesions are located anteriorly and supplied by the anterior spinal artery (ASA). ASA can also vascularize shunts located on the posterior surface of the spinal cord either by transmedullary arteries, pial circumferential arteries or, if affecting the lower portions of the cord, by the anastomotic channels of the basket. Each of these vessels can be used for endovascular navigation to reach the shunts with good results if appropriate anatomical rules are followed. We describe here some technical considerations based on the anatomical analysis for the embolization of posterior spinal cord arteriovenous shunts vascularized by the anterior spinal artery.
A medical probe device including a catheter having a stylet guide housing with one or more stylet ports in a side wall thereof and guide means for directing a flexible stylet outward through the stylet port and through intervening tissue to a target tissue. The catheter assembly includes a stylet guide lumen communicating with the stylet port and a stylet positioned in said stylet guide lumen for longitudinal movement from the port through intervening tissue to a target tissue. The stylet can be an electrical conductor enclosed within a non-conductive layer, the electrical conductor being a radio frequency electrode. In normal action, the stylet and its surrounding sleeve are deployed out from the stylet port in the catheter into the desired target tissue. A sharpened tip on the stylet electrode facilitates the penetration of the intervening tissue, such as a urethra. If, however, the stylet is deployed into a dense or fibrous area of tissue or into an area of scar tissue in the urethra, the sharpened tip of the stylet might not immediately penetrate the urethra wall until sufficient pressure is applied to the stylet. By heating the stylet prior to extension of the stylet from the stylet port in the catheter, the passage of the stylet through the intervening tissue is facilitated. Once the stylet is in position in the target tissue, the normal operation of the stylet in emitting electromagnetic current for tissue ablation is commenced.
The subject of the invention relates to a skin product comprising the extract of the plant Anthemis rosea subsp. carnea, which inhibits the growth of pathogenic microorganisms in the product where it is added and which does not deteriorate the skin health owing to being natural. The extract, juice (hydrolate) or essential oil obtained from the capitula of the flowers of the plant Anthemis rosea subsp. carnea, or mixtures of these, may be used as the extract of said plant. The extract of the plant Anthemis rosea subsp. carnea, owing to having the antioxidant property in addition to being natural and having the antimicrobial property, enhances the cell viability and provides the skin care. Owing to comprising said extract with multiple actions, the skin product alone provides multiple benefits to the skin by means of a single agent.
This study aims to analyze the risk factors associated with delayed postoperative bleeding (DPPB) following colorectal polyp surgery, develop a dynamic nomogram and evaluate the model efficacy, provide a reference for clinicians to identify the patients at high risk of DPPB. Retrospective study was done on patients who underwent endoscopic colorectal polypectomy at the First Hospital of Lanzhou University from January 2020 to March 2023. Differences between the group with and without DPPB were compared, and independent risk factors for DPPB occurrence were identified through univariate analysis and combination LASSO and logistic regression. A dynamic nomogram was constructed based on multiple logistic regression to predict DPPB following colorectal polyp surgery. Model evaluation included receiver operating characteristic (ROC), Calibration curve, Decision curve analysis (DCA). DPPB occurred in 38 of the 1544 patients included. multivariate analysis showed that direct oral anticoagulants (DOACs), polyp location in the right hemi colon, polyp diameter, drink, and prophylactic hemoclips were the independent risk factors for DPPB and dynamic nomogram were established. Model validation indicated area under the ROC curve values of 0.936, 0.796, and 0.865 for the training set, validation set, and full set, respectively. The calibration curve demonstrated a strong alignment between the predictions of the column-line diagram model and actual observations. The decision curve analysis (DCA) displayed a significant net clinical benefit across the threshold probability range of 0-100%. The dynamic nomogram aids clinicians in identifying high-risk patients, enabling personalized diagnosis and treatment.
PURPOSE:An antitumor agent containing a specific glycerol derivative. CONSTITUTION:An antitumore agent effective against leukemia, solid cancer, etc., containing a compound shown by the formula I (R<1> is alkyl, or alkylcarbamoyl; R<2> and R<3> are H, lower alkyl, or R<1> and R<2> together with neighboring N form ring). It has low toxicity, and administered orally or parenterally to the whole body or the affected part. A dose is preferably 50 mg-2g/day and it is administered dividedly once-several times daily or by installation. The compound shown by the formula I is obtained by reacting a compound shown by the formula II (R<4> is protecting group) with a compound shown by the formula III (X is Cl, or Br), and eliminating the protecting group R<4>. This composition may contain other active components as long as no unfavorable mutual action is produced by blending with the compound shown by the formula I.
BACKGROUND: Melanoma is a highly aggressive tumor, predominantly found in the skin, recognized as skin cutaneous melanoma (SKCM). Lymph node metastasis is commonly used as the route of metastasis in SKCM, necessitating the discovery of prognostic genes associated with this process for improved prognosis.
METHODS: The prognostic significance of lymph node metastasis in SKCM was assessed through Kaplan-Meier analysis in SEER and TCGA-SKCM datasets. Prognostic genes were identified and a prognostic risk model was constructed Enrichment analysis and immune cell infiltration analysis were also carried out.Moreover, a validation in vitro and in vivo were conducted by CCK8,flow cytometry, transwell and animal study.
RESULTS: The Kaplan-Meier survival curve revealed that patients with lymph node metastasis had a worse prognosis compared to those without. FCGR3B and PRF1 were screened by TCGA analysis.Additionally, significant differences in nine immune cell types were observed between the two risk groups. Notably, a strong positive association with CD8 T cells and a negative relationship with M2 macrophages were exhibited by PRF1. The validation of our nomogram were conducted in vitro and in vivo, and the results showed the correlations between CD8+ T cell and PRF1.
CONCLUSION: In summary, two prognostic genes (FCGR3B and PRF1) were identified, and a prognostic risk model was developed for SKCM. These findings provide a novel approach for the diagnosis and treatment of SKCM.
PURPOSE:To provide a skin external agent containing glycyrrhetinic acid monoglucuronide or its salt as an active ingredient, and effective for preventing skin roughness, skin inflammation, skin UV ray erythema, etc., and for mitigating skin irritation caused by irritative substances. CONSTITUTION:A skin external agent containing as an active ingredient glycyrrhetinic acid monoglucuronide obtained by enzymatically partially hydrolyzing glycyrrhizin to remove a glucuronic acid molecule in its saccharide part, or its salt. The active ingredient exhibits an almost twice potency that of the glycyrrhizin, gives solutions having excellent stability, and is weak in foamability. The skin external agent is a new safe and easily usable skin external agent. The external agent can be used for medicines, qusidrugs, various cosmetics, shampoos, rinses, packs, soaps, bath agents, hair-raising agents, etc. When the external agent is added to the cosmetic, the external agent is used in an amount of approximately 0.001-5wt.% as the glycyrretinic acid monoglucuronide.
BACKGROUND: Chronic myeloid leukaemia (CML) is a type of blood cancer that begins in the hematopoietic stem cells. It is primarily characterized by a specific chromosomal aberration, the Philadelphia chromosome. While the fusion gene is a major contributor to CML, several other genes including ADGRE2, that are reported as highly expressed in hematopoietic stem cells and could be utilized as a therapeutic marker in leukemic patients are implicated in the disease's progression. Until recently, little research had been conducted to identify single nucleotide polymorphisms (SNPs) associated with CML. Therefore, this study aims to investigate the influence of non-synonymous variants on the structure and function of the gene encoding adhesion G protein-coupled receptor E2, ADGRE2, and to evaluate their association with CML and its clinical and pathological characteristics.
METHODS: Non-synonymous SNPs of ADGRE2 were retrieved from the ENSEMBL, COSMIC, and gnomAD genome browsers, and the pathogenicity of deleterious variants was assessed using several established computational tools, including SIFT, CADD, REVEL, PolyPhen, and MetaLR.
RESULTS: Various in silico analyses explored the impact of damaging SNP on the function, stability, and structure of EGF-like modules containing mucin-like hormone receptor-like2 (EMR2) protein encoded by the ADGRE2 gene. Genotype analysis was performed on collected blood samples, revealing that altered genotype TT of variant rs765071211 (C/T) was associated significantly with CML patients compared to the control. Further in vitro and in vivo analyses suggest that this SNP holds potential for clinical translation.
The invention relates to a method for treating blood coagulation dysfunction by using vitamin K1 fat emulsion injection. In particular, the invention relates to an emulsion composition comprising vitamin K1, soybean oil, phospholipids, glycerol and water. The emulsion composition is prepared by the processes of preparing a water phase, preparing an oil phase, preparing coarse emulsion, emulsifying under high pressure, sterilizing under hot pressure and the like, and the operation of detecting related substances, particularly impurity B, of the emulsion composition obtained by sterilizing under hot pressure is also included. The invention also relates to the pharmaceutical application of the emulsion composition, which is used for treating blood coagulation dysfunction diseases caused by blood coagulation factor II, VII, IX and X synthesis disorders caused by vitamin K deficiency or drug intervention of interfering vitamin K activity. The invention also relates to a method for determining related substances, in particular to impurity B in the vitamin K1 composition by using an HPLC method. The emulsion compositions of the present invention exhibit one or more of the technical effects described in the specification.
The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
PURPOSE:To provide a new external agent for skin containing an additive which can increase pyrrolidonecarboxylic acid and utilizing the increasing process. CONSTITUTION:A method for increasing pyrrolidonecarboxylic acid by coating the skin surface with mucilage from NATTO (fermented soybeans) or glutamic acid polymer. Further, skin external agent containing NATTO mucilage or glutamic acid polymer and utilizing the increasing method. The increase of pyrrolidone-carboxylic acid improves humectant properties. These substances are safe to the skins with good application feeling, when they are added to the external agent. Additionally, the skin becomes elastic and the skin can effectively be prevented from drying.
Severe clinical complications including acute rejection and opportunistic infections in solid organ transplantation (SOT) are mainly caused by inadequate impairment of cell-mediated immunity (CMI) by immunosuppressive therapy. In particular CMV is responsible for increased morbidity and mortality revealing the need for either prophylactic or preemptive antiviral treatment. Recipients with negative CMV serology (R-) receiving a graft from a seropositive donor (D+) are at highest risk of developing CMV-associated complications. Therefore, these patients usually receive antiviral prophylaxis whereas patients at intermediate risk (D+/R+ or D-/R+) are treated either prophylactically or preemptively. Although prophylaxis is efficient, it is also accompanied by harmful side effects and high costs. Thus, there is a need for a personalized antiviral as well as immunosuppressive therapy to optimally treat the patient and to improve long-term patient and graft survival. The detection of a protective threshold of functional CMV-reactive cells may help to predict the onset of viral complications, thereby minimizing harmful side effects. Currently available tools to measure CMV-specific cellular immunity reveal striking limitations including a lack of standardization necessitating a commercially available standardized test system. The Lophius kit T-Track® CMV represents a highly standardized and sensitive diagnostic tool to assess the functionality of a network of clinically relevant CMV-reactive effector cells. It is based on the stimulation of peripheral blood mononuclear cells (PBMC) with urea-formulated immunodominant CMV proteins, pp65 and IE-1, and the subsequent quantification of CMV-specific CMI (spot forming colonies) using a highly sensitive IFN-γ ELISpot. This study aims to assess the suitability of the Lophius Biosciences kit T-Track® CMV to determine the CMV-specific CMI in renal transplant recipients scheduled for a preemptive antiviral treatment strategy. Furthermore, it will be investigated if the results obtained with T-Track® CMV are suitable to define a cut-off value of CMV-specific CMI mediating protection from CMV reactivations and related complications. Moreover, possible associations between CMV-specific CMI measured with T-Track® CMV and clinical complications including acute rejection episodes and opportunistic infections will be analyzed as well as the influence of the immunosuppressive treatment and the patient's HLA type on viral immunity.
PCT No. PCT/DK87/00086 Sec. 371 Date Feb. 24, 1988 Sec. 102(e) Date Feb. 24, 1988 PCT Filed Jul. 8, 1987 PCT Pub. No. WO88/00045 PCT Pub. Date Jan. 14, 1988.A method of preparing powdered, free-flowing tocopheryl succinate having a high bulk density comprising melting a mixture of tocopheryl succinate and wax, spraying the melt in a spraying zone containing a cloud of a powdering agent consisting of fine tocopheryl succinate and an additional powdering agent, and maintaining the product formed in a fluidized state by introducing cooling air until the tocopheryl succinate particles have hardened, and separating the product formed into a product fraction and a fine fraction, and recyclying the fine fraction to the spraying zone.